Metagenomi Announces New Appointment to its Board of Directors
Metagenomi (Nasdaq: MGX) has announced the appointment of Eric Bjerkholt, MBA, to its Board of Directors, effective January 27, 2025. Bjerkholt, currently CFO of Mirum Pharmaceuticals, will serve on Metagenomi's Audit and Compensation committees.
Bjerkholt brings significant pharmaceutical industry experience, having served as CFO at several companies including Chinook Therapeutics (acquired by Novartis AG) and Aimmune Therapeutics (acquired by Nestle Health Science). At Sunesis Pharmaceuticals, he held multiple executive roles including Executive VP of Corporate Development and Finance. His background includes healthcare investment banking at J.P. Morgan and senior finance roles at various companies.
Metagenomi (Nasdaq: MGX) ha annunciato la nomina di Eric Bjerkholt, MBA, nel suo Consiglio di Amministrazione, a partire dal 27 gennaio 2025. Bjerkholt, attualmente CFO di Mirum Pharmaceuticals, farà parte dei comitati di Revisione e Compensazione di Metagenomi.
Bjerkholt porta con sé un'esperienza significativa nell'industria farmaceutica, avendo ricoperto il ruolo di CFO in diverse aziende, tra cui Chinook Therapeutics (acquisita da Novartis AG) e Aimmune Therapeutics (acquisita da Nestle Health Science). Presso Sunesis Pharmaceuticals, ha ricoperto diversi ruoli dirigenziali, tra cui quello di VP Esecutivo dello Sviluppo Aziendale e Finanza. Il suo background include anche esperienze nella consulenza finanziaria sanitaria presso J.P. Morgan e ruoli dirigenziali in varie aziende.
Metagenomi (Nasdaq: MGX) ha anunciado el nombramiento de Eric Bjerkholt, MBA, a su Junta Directiva, a partir del 27 de enero de 2025. Bjerkholt, actualmente CFO de Mirum Pharmaceuticals, formará parte de los comités de Auditoría y Compensación de Metagenomi.
Bjerkholt aporta una experiencia significativa en la industria farmacéutica, habiendo sido CFO en varias empresas, incluyendo Chinook Therapeutics (adquirida por Novartis AG) y Aimmune Therapeutics (adquirida por Nestlé Health Science). En Sunesis Pharmaceuticals, ocupó múltiples roles ejecutivos, incluyendo el de VP Ejecutivo de Desarrollo Corporativo y Finanzas. Su trayectoria incluye banca de inversión en salud en J.P. Morgan y roles financieros superiores en diversas empresas.
메타게노미(Metagenomi) (Nasdaq: MGX)는 에릭 비에르크홀트(경영학 석사)를 이사의 회의에 임명했다고 발표했습니다, 2025년 1월 27일부터 발효됩니다. 현재 미룸 제약 회사의 CFO인 비에르크홀트는 메타게노미의 감사 및 보상 위원회에서 활동할 것입니다.
비에르크홀트는 노바르티스 AG에 인수된 치누크 치료제와 네슬레 헬스 사이언스에 인수된 아이뮤니티 치료제 등 여러 회사에서 CFO로 근무하며 제약산업에서 상당한 경험을 쌓았습니다. 선시스 제약에서는 기업 개발 및 재무의 EVP를 포함한 다수의 임원 역할을 수행했습니다. 그의 경력은 JP모건에서의 헬스케어 투자은행 및 여러 회사에서의 고위 재무 역할을 포함합니다.
Metagenomi (Nasdaq: MGX) a annoncé la nomination d'Eric Bjerkholt, MBA, à son Conseil d'Administration, à compter du 27 janvier 2025. Bjerkholt, actuellement CFO de Mirum Pharmaceuticals, siégera aux comités d'Audit et de Rémunération de Metagenomi.
Bjerkholt apporte une expérience significative dans l'industrie pharmaceutique, ayant été CFO dans plusieurs entreprises, dont Chinook Therapeutics (acquise par Novartis AG) et Aimmune Therapeutics (acquise par Nestlé Health Science). Chez Sunesis Pharmaceuticals, il a occupé plusieurs postes de direction, notamment celui de VP Exécutif du Développement Corporatif et Financier. Son parcours comprend des expériences en banque d'investissement dans le secteur de la santé chez J.P. Morgan et des rôles financiers supérieurs dans diverses entreprises.
Metagenomi (Nasdaq: MGX) hat die Ernennung von Eric Bjerkholt, MBA, in seinen Vorstand bekannt gegeben, wirksam ab dem 27. Januar 2025. Bjerkholt, der derzeit CFO von Mirum Pharmaceuticals ist, wird in den Prüfungs- und Vergütungsausschüssen von Metagenomi tätig sein.
Bjerkholt bringt umfangreiche Erfahrung in der pharmazeutischen Industrie mit, da er CFO bei mehreren Unternehmen war, darunter Chinook Therapeutics (erworben von Novartis AG) und Aimmune Therapeutics (erworben von Nestlé Health Science). Bei Sunesis Pharmaceuticals hatte er mehrere Führungspositionen inne, darunter die des Executive VP für Unternehmensentwicklung und Finanzen. Sein Hintergrund umfasst auch Investment Banking im Gesundheitswesen bei J.P. Morgan sowie leitende Finanzpositionen in verschiedenen Unternehmen.
- Appointment of experienced CFO with track record in pharmaceutical industry
- New director brings expertise in business development and capital formation
- Addition of board member with experience in successful company acquisitions
- None.
EMERYVILLE, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced that Eric Bjerkholt, MBA, CFO of Mirum Pharmaceuticals, Inc., will join Metagenomi’s Board of Directors, serving on Metagenomi’s Audit and Compensation committees, effective January 27, 2025.
“We are excited to welcome Eric to our Board of Directors,” said Brian C. Thomas, PhD, CEO and founder of Metagenomi. “His tremendous track record in the pharmaceutical industry as well as his experience in business development and capital formation will be an invaluable asset to Metagenomi as we continue to advance potentially curative treatment options for patients suffering from devastating disease.”
“I am thrilled to join Metagenomi at this important time of innovation and clinical validation in the broader gene editing space,” said Eric Bjerkholt, MBA, CFO of Mirum Pharmaceuticals. “I am excited to collaborate with the Board and the management team, which brings together some of the brightest innovators and industry veterans, to accelerate our development of precision genetic medicines.”
Mr. Bjerkholt brings extensive business leadership experience across a broad range of roles and is currently Chief Financial Officer of Mirum Pharmaceuticals, Inc. He joined Mirum from Chinook Therapeutics, Inc. where he also served as CFO overseeing financial reporting, planning and budgeting, internal controls, investor relations, facilities, and information technology functions. Chinook was acquired by Novartis AG. Prior to Chinook, Mr. Bjerkholt was CFO of Aimmune Therapeutics, which was acquired by Nestle Health Science. Previously Mr. Bjerkholt worked at Sunesis Pharmaceuticals, Inc., where in addition to CFO, he served in various capacities, including Executive Vice President of Corporate Development and Finance, Corporate Secretary and Chief Compliance Officer. Mr. Bjerkholt has also held senior executive finance roles at IntraBiotics Pharmaceuticals, Inc., LifeSpring Nutrition, Inc. and Age Wave, LLC and spent seven years in healthcare investment banking at J.P. Morgan & Company, Inc. Mr. Bjerkholt holds an MBA from Harvard Business School and a Cand.oecon. from the University of Oslo in Norway.
About Metagenomi
Metagenomi is a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived toolbox. Metagenomi is harnessing the power of metagenomics, the study of genetic material recovered from the natural environment, to unlock four billion years of microbial evolution to discover and develop a suite of novel editing tools capable of correcting any type of genetic mutation found anywhere in the genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems (including prime editing systems and clustered regularly interspaced short palindromic repeat associated transposases (CAST)). Metagenomi believes its diverse and modular toolbox positions the company to access the entire genome and select the optimal tool to unlock the full potential of genome editing for patients. For more information, please visit https://metagenomi.co.
Cautionary Note Regarding Forward‐Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions, include, but are not limited to, any statements relating to our growth strategy and product development programs, including the timing of and our ability to conduct IND-enabling studies, make regulatory filings such as INDs, statements concerning the potential of therapies and product candidates, and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition, and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under, and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in “Risk Factors,” in our most recent Form 10-K and our most recent 10-Qs on file with the Securities and Exchange Commission. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Contact:
Simon Harnest - CIO, SVP Investor Relations
IR@metagenomi.co
FAQ
When will Eric Bjerkholt join Metagenomi's (MGX) Board of Directors?
What committees will Eric Bjerkholt serve on at Metagenomi (MGX)?
What is Eric Bjerkholt's current role outside of Metagenomi (MGX)?
What notable companies has Eric Bjerkholt previously worked with before joining MGX's board?
